Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.63 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.63 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | JAK1 | P23458 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10220549 | 0.90 | CHEK1 (0.78) | CHEK1CHEK2JAK2JAK1JAK3 | |
| SCHEMBL10171746 | 0.88 | CHEK1 (0.64) | CHEK1CHEK2JAK2JAK1JAK3 | |
| SCHEMBL10172276 | 0.81 | KAT2B (0.51) | CHEK1CHEK2KAT2BBRD4ATAD2 | |
| SCHEMBL10218115 | 0.81 | CHEK1 (0.76) | CHEK1CHEK2JAK2JAK1JAK3 | |
| SCHEMBL618145 | 0.80 | CHEK1 (0.75) | CHEK1CHEK2JAK2JAK1JAK3 | |
| SCHEMBL620218 | 0.77 | CHEK1 (1.00) | CHEK1CHEK2JAK2JAK1JAK3 | |
| SCHEMBL620217 | 0.77 | CHEK1 (1.00) | CHEK1CHEK2JAK2JAK1JAK3 | |
| SCHEMBL12122908 | 0.77 | CHEK1 (0.83) | CHEK1CHEK2JAK2JAK1JAK3 | |
| SCHEMBL13893642 | 0.77 | CHEK1 (0.71) | CHEK1CHEK2JAK2JAK1JAK3 | |
| SCHEMBL620398 | 0.75 | CHEK1 (0.76) | CHEK1CHEK2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367658-B2 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-05 | — | — | US | disclosed |
| US-20120040967-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-8058045-B2 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040967-A1 | Pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine Compounds and Their Use | CHEK1, CHEK2, PLK1 | CHEK1 1/4885CHEK2 2/4885JAK2 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.